Viatris (VTRS)
(Delayed Data from NSDQ)
$11.39 USD
+0.01 (0.09%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:02 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.39 USD
+0.01 (0.09%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $11.40 +0.01 (0.09%) 7:02 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
Zacks News
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed at $9.97 in the latest trading session, marking a +1.94% move from the prior day.
Viatris (VTRS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Viatris (VTRS) closed at $9.61, marking a +0.63% move from the previous day.
Merck's (MRK) Stock Up on Januvia Patent Win Against Viatris
by Zacks Equity Research
Merck (MRK) gets a favorable ruling from a district court of West Virginia in two patents related to Januvia/Janumet against Viatris, which is looking to market its generic versions of the medicines in the United States
Why Is Viatris (VTRS) Down 10% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Aug 9, 2022
by Zacks Equity Research
Companies in The News Are: GOLD,HE,BNTX,VTRS
Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Viatris (VTRS) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris Q2 Preview: Can Shares Snap Their Downtrend?
by Derek Lewis
Even over the last month, when the S&P 500 has rallied for an 8% gain, Viatris shares have continued their downwards trajectory, declining 5.5% in value.
Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline
by Zacks Equity Research
Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avantor, Inc. (AVTR) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of -2.63% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Up 13.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Viatris (VTRS) Q1 Earnings Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 4.17% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.21, moving -1.16% from the previous trading session.
Earnings Preview: Viatris (VTRS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.39, moving +1.07% from the previous trading session.
Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.92, moving +1.96% from the previous trading session.
Viatris (VTRS) Stock Moves -0.28%: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.67, moving -0.28% from the previous trading session.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $10.67, moving -1.66% from the previous trading session.
Theravance's (TBPH) Hypotension Study Misses Primary Goal
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.